+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Kidney Cancer (Renal Cell Cancer) (Oncology) - Drugs in Development, 2021

  • PDF Icon

    Report

  • 4110 Pages
  • December 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5521231
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2021, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 1, 24, 206, 212, 5, 16, 127, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 15, 11, 2, 1, 16 and 1 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Report Coverage
  • Kidney Cancer (Renal Cell Cancer) - Overview
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development
  • Kidney Cancer (Renal Cell Cancer) - Drug Profiles
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products
  • Kidney Cancer (Renal Cell Cancer) - Product Development Milestones

Featured News & Press Releases
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Kidney Cancer (Renal Cell Cancer) - Dormant Projects, 2021
  • Kidney Cancer (Renal Cell Cancer) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3D Medicines Inc
  • 4D Pharma Plc
  • 4SC AG
  • Aadi Bioscience Inc
  • Abbisko Therapeutics Co Ltd
  • AbbVie Inc
  • ABL Bio Inc
  • Achilles Therapeutics UK Ltd
  • Acrotech Biopharma LLC
  • Actuate Therapeutics Inc
  • Adagene Suzhou Ltd
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics SA
  • Adlai Nortye Biopharma Co Ltd
  • Advenchen Laboratories LLC
  • Affimed GmbH
  • Affitech A/S
  • Agenus Inc
  • AIM ImmunoTech Inc
  • Akeso Inc
  • Alkermes Plc
  • Allarity Therapeutics A/S
  • Alligator Bioscience AB
  • Almac Discovery Ltd
  • Alpha-1 Biologics Corp
  • AlphaMab Co Ltd
  • Alphamab Oncology
  • Altor Bioscience LLC
  • ALX Oncology Holdings Inc
  • Ambrx Biopharma Inc
  • Amgen Inc
  • Amphivena Therapeutics Inc
  • Anaveon AG
  • Anhui Anke Biotechnology (Group) Co Ltd
  • AntiCancer Inc
  • Apcure SAS
  • Apexigen Inc
  • Apollomics Inc
  • Aprea Therapeutics Inc
  • Aprilbio Co Ltd
  • Aravive Inc
  • Arcus Biosciences Inc
  • Argenx SE
  • Arrowhead Pharmaceuticals Inc
  • Ascentage Pharma Group International
  • Ashvattha Therapeutics LLC
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atreca Inc
  • Aurigene Discovery Technologies Ltd
  • Avesthagen Ltd
  • Bacchus Therapeutics Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beijing Eastern Biotech Co Ltd
  • Beijing Foreland Pharma Co Ltd
  • Beijing Kawin Technology Share-Holding Co Ltd
  • Beijing Konruns Pharmaceutical Co Ltd
  • Beijing Scitech-MQ Pharmaceuticals Ltd
  • Benhealth Biopharmaceutical (Shenzhen) Co Ltd
  • BerGenBio ASA
  • BeyondSpring Inc
  • Bicycle Therapeutics Plc
  • Bio-Path Holdings Inc
  • Bio-Thera Solutions Ltd
  • BioAtla Inc
  • Biocad
  • Biocon Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioIntegrator Ltd
  • Biomica
  • Bionomics Ltd
  • BioNTech SE
  • Biosion Inc
  • Biotheus Inc
  • BioVaxys Technology Corp
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • BridgeBio Pharma Inc
  • Bristol-Myers Squibb Co
  • Byondis BV
  • Calico Life Sciences LLC
  • Calithera Biosciences Inc
  • CanBas Co Ltd
  • Canget BioTekpharma LLC
  • Cantargia AB
  • Catamaran Bio Inc
  • Cbiomex Co Ltd
  • Celdara Medical LLC
  • Celldex Therapeutics Inc
  • Celyad Oncology SA
  • Centurion BioPharma Corp
  • CG Oncology Inc
  • Checkpoint Therapeutics Inc
  • CicloMed LLC
  • Clovis Oncology Inc
  • COARE Biotechnology Inc
  • Coherent Biopharma
  • CoImmune Inc
  • Constellation Pharmaceuticals Inc
  • Corvus Pharmaceuticals Inc
  • Cothera Bioscience Pty Ltd
  • CRISPR Therapeutics AG
  • CSPC Pharmaceutical Group Ltd
  • CureLab Oncology Inc
  • Curigin Co Ltd
  • Curis Inc
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Deciphera Pharmaceuticals Inc
  • Deka Biosciences Inc
  • DevaCell Inc
  • DNAtrix Inc
  • Dragonboat Biopharmaceutical (Shanghai) Co Ltd
  • Dragonfly Therapeutics Inc
  • Duet Therapeutics Inc
  • Dyadic International Inc
  • Ecrins Therapeutics SAS
  • Eddingpharm Inc
  • eFFECTOR Therapeutics Inc
  • EirGenix Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Ella Therapeutics Ltd
  • Ellipses Pharma Ltd
  • Enara Bio Ltd
  • Enochian Biosciences Inc
  • EpimAb Biotherapeutics Inc
  • Epizyme Inc
  • Epygen Biotech Pvt Ltd
  • Esanex Inc
  • Esperance Pharmaceuticals Inc
  • eTheRNA Immunotherapies NV
  • Evaxion Biotech ApS
  • Exelixis Inc
  • EXUMA Biotech Inc
  • F-star Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics Inc
  • G1 Therapeutics Inc
  • GEMoaB Monoclonals GmbH
  • Genentech USA Inc
  • Geneos Therapeutics Inc
  • Generium
  • GenFleet Therapeutics (Shanghai) Inc
  • Genmab AS
  • Genocea Biosciences Inc
  • Genome & Co
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • GLG Pharma SA
  • Glycotope GmbH
  • GlyTherix Ltd
  • GT Biopharma Inc
  • Guangzhou BeBetter Medicine Technology Co Ltd
  • Guangzhou Hanghua Bio Pharmaceutical Technology Co
  • Hainan Kaibo Biotechnology Co Ltd
  • Handa Pharmaceuticals LLC
  • Hangzhou Zenshine Pharmaceuticals Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Harbour BioMed (Guangzhou) Co Ltd
  • Helixmith Co Ltd
  • Hengenix Biotech Inc
  • Hibercell Inc
  • HitGen Inc
  • Horizon Therapeutics Plc
  • Hualan Biological Engineering Inc
  • Hutchison MediPharma Ltd
  • I-Mab
  • Idera Pharmaceuticals Inc
  • Ikena Oncology Inc
  • Immune Pharmaceuticals Inc
  • Immune Therapeutics Inc
  • ImmuneCyte Inc
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • ImmuneSensor Therapeutics Inc
  • Immunicum AB
  • ImmunityBio Inc
  • Immunocore Holdings Plc
  • ImmunoGen Inc
  • Imugene Ltd
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Inhibrx Inc
  • Inmune Bio Inc
  • InnoCare Pharma Ltd
  • Innovative Cellular Therapeutics Co Ltd
  • Innovent Biologics Inc
  • InSight Biopharmaceuticals Ltd (Inactive)
  • InteRNA Technologies BV
  • Invectys SA
  • IO Biotech Inc
  • Istari Oncology Inc
  • Iterion Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • JSK Therapeutics Inc
  • Jubilant Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Kidswell Bio Corp
  • Kind Pharmaceuticals
  • Kinnate Biopharma Inc
  • Kintor Pharmaceutical Ltd
  • KLUS Pharma Inc
  • Komipharm International Co Ltd
  • Kuda Therapeutics Inc
  • Kymab Ltd
  • Kyowa Kirin Co Ltd
  • LaNova Medicines Ltd
  • Lantern Pharma Inc
  • Lead Discovery Center GmbH
  • Lindis Biotech GmbH
  • Lipac Oncology LLC
  • Lotus Pharmaceutical Co Ltd
  • Loxo Oncology Inc
  • Luye Pharma Group Ltd
  • Lycera Corp
  • Lytix Biopharma AS
  • Mabwell Shanghai Bioscience Co Ltd
  • MacroGenics Inc
  • Mana Therapeutics Inc
  • Mantis Therapeutics BV
  • Marino Biotechnology Co Ltd
  • MaxiVAX SA
  • MdBioLab
  • Medicenna Therapeutics Corp
  • MediciNova Inc
  • MedPacto Inc
  • Merck & Co Inc
  • Merck KGaA
  • Metagone Biotech Inc
  • Metis Precision Medicine
  • Microbiotica Ltd
  • MicuRx Pharmaceuticals Inc
  • Midissia Therapeutics Inc
  • Millennium Pharmaceuticals Inc
  • Mirati Therapeutics Inc
  • Miyarisan Pharmaceutical Company Ltd
  • Moderna Inc
  • Modulation Therapeutics Inc
  • Molecular Partners AG
  • Molecular Templates Inc
  • Moleculin Biotech Inc
  • Multitude therapeutics Inc
  • MultiVir Inc
  • Mycenax Biotech Inc
  • Nanjing Aimeifei Biomedical Technology Co Ltd
  • NanoCarrier Co Ltd
  • Nanology LLC
  • Nektar Therapeutics
  • Neoleukin Therapeutics Inc
  • NeoTX Therapeutics Ltd
  • NeuClone Pty Ltd
  • New Beta Innovation Ltd
  • NGM Biopharmaceuticals Inc
  • NiKang Therapeutics Inc
  • Novartis AG
  • Nurix Therapeutics Inc
  • Ocellaris Pharma Inc
  • Ocuphire Pharma Inc
  • Omeros Corp
  • OncoC4 Inc
  • Oncolys BioPharma Inc
  • Onconova Therapeutics Inc
  • OncoQuest Inc
  • Oncorena AB
  • Oncorus Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Orion Corp
  • Orpheus Therapeutics Inc
  • Pact Pharma Inc
  • Pathios Therapeutics Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAbcine Inc
  • PharmaTher Holdings Ltd
  • Pharmicell Co Ltd
  • Philogen SpA
  • Phosplatin Therapeutics LLC
  • Pinotbio Inc
  • Pionyr Immunotherapeutics Inc
  • PlantForm Corp
  • Prestige BioPharma Ltd
  • PsiOxus Therapeutics Ltd
  • Qilu Pharmaceutical Co Ltd
  • Qilu Puget Sound Biotherapeutics Corp
  • Qu Biologics Inc
  • Quadriga BioSciences Inc
  • Qualigen Therapeutics Inc
  • Race Oncology Ltd
  • RAPT Therapeutics Inc
  • Recombio SL
  • Regeneron Pharmaceuticals Inc
  • RemeGen Co Ltd
  • Repertoire Immune Medicines Inc
  • Replimune Ltd
  • RevImmune SAS
  • Richter Gedeon Nyrt
  • Rizen (Suzhou) Biosciences Co Ltd
  • Ryvu Therapeutics SA
  • SA Science Inc
  • Samyang Biopharmaceuticals Corp
  • Sanofi
  • Sapphire Biotech Inc
  • Sareum Holdings Plc
  • Scancell Holdings Plc
  • Scholar Rock Inc
  • Schrodinger Inc
  • Seagen Inc
  • SELLAS Life Sciences Group Inc
  • Seneca Therapeutics Inc
  • Serum Institute of India Pvt Ltd
  • Seven and Eight Biopharmaceuticals Corp
  • Shandong New Time Pharmaceutical Co Ltd
  • Shandong Taize Huikang Biomedical Co Ltd
  • Shanghai De Novo Pharmatech Co Ltd
  • Shanghai Escugen Biotechnology Co Ltd
  • Shanghai Haihe Biopharma Co Ltd
  • Shanghai Henlius Biotech Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Miracogen Inc
  • Shanghai Pharmaceutical Group Co Ltd
  • Shattuck Labs Inc
  • Shenzhen Chipscreen Biosciences Co Ltd
  • Shijiazhuang Yiling Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Sichuan Huiyang Life Science and Technology Corp
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sichuan Sinovation Bio-technology Co Ltd
  • SignalRx Pharmaceuticals Inc
  • Sillajen Biotherapeutics
  • Silverback Therapeutics Inc
  • Simcha Therapeutics Inc
  • Sonnet BioTherapeutics Holdings Inc
  • Sonoval LLC
  • Sorrento Therapeutics Inc
  • Sotio AS
  • ST Pharm Co Ltd
  • STADA Pharmaceuticals (Asia) Ltd
  • Statera BioPharma Inc
  • Steba Biotech SA
  • Sumitomo Dainippon Pharma Co Ltd
  • Sumitomo Dainippon Pharma Oncology, Inc
  • Suntec Medical (Taiwan) Inc
  • Surface Oncology Inc
  • Suzhou Dingfu Target Biotechnology Co Ltd
  • Suzhou Stainwei Biotech Inc
  • Syndivia SAS
  • Synermore Biologics Co Ltd
  • SynOx Therapeutics Ltd
  • Systimmune Inc
  • T-Cure Bioscience Inc
  • Tactical Therapeutics Inc
  • TAE Life Sciences LLC
  • Taiho Oncology Inc
  • Taiho Pharmaceutical Co Ltd
  • Tarus Therapeutics Inc
  • TCR2 Therapeutics Inc
  • Telix Pharmaceuticals Ltd
  • Tempest Therapeutics Inc
  • Teon Therapeutics Inc
  • Theralink Technologies Inc
  • Toray Industries Inc
  • TotalClarity Inc
  • Treadwell Therapeutics Inc
  • Turning Point Therapeutics Inc
  • TVAX Biomedical Inc
  • Tyme Inc
  • UbiVac LLC
  • UCB SA
  • Unicyte AG
  • VasGene Therapeutics Inc
  • Vault Pharma Inc
  • Vaxiion Therapeutics Inc
  • Versameb AG
  • Viatris Inc
  • Vincerx Pharma Inc
  • Vyriad Inc
  • Western Oncolytics Ltd
  • WindMIL Therapeutics Inc
  • X4 Pharmaceuticals Inc
  • Xbrane Biopharma AB
  • Xcovery Holding Co LLC
  • Xencor Inc
  • Xilio Therapeutics Inc
  • Xynomic Pharmaceuticals Holdings Inc
  • Y-Biologics Inc
  • Y-mAbs Therapeutics Inc
  • Yantai Rongchang Pharmaceutical Co Ltd
  • Yuhan Corp
  • Zelluna Immunotherapy AS
  • Zymergen Inc